Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 12/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | GALR2 | O43603 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.37 |
| ▸ | ERG | P11308 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12330776 | 0.94 | PTGDR (0.42) | PTGDRIGF1RALKKDM4ECNR2 | |
| SCHEMBL12330969 | 0.94 | PTGDR (0.42) | PTGDRIGF1RALKKDM4ECNR2 | |
| SCHEMBL12330775 | 0.94 | PTGDR (0.43) | PTGDRIGF1RALKKDM4ECNR2 | |
| SCHEMBL12330827 | 0.92 | PTGDR (0.41) | PTGDRIGF1RALKKDM4ECNR2 | |
| SCHEMBL2452143 | 0.91 | PTGDR (0.45) | PTGDRIGF1RALKKDM4ECNR2 | |
| SCHEMBL12331083 | 0.91 | PTGDR (0.45) | PTGDRIGF1RALKKDM4ECNR2 | |
| SCHEMBL2448896 | 0.91 | PTGDR (0.45) | PTGDRIGF1RALKKDM4ECNR2 | |
| SCHEMBL14354347 | 0.91 | PTGDR (0.45) | PTGDRIGF1RALKKDM4ECNR2 | |
| SCHEMBL12331942 | 0.91 | PTGDR (0.39) | PTGDRIGF1RALKKDM4ECNR2 | |
| SCHEMBL12331284 | 0.89 | PTGDR (0.40) | PTGDRIGF1RALKKDM4ECNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547673-A1 | A SUBSTITUTED PYRIMIDINE AS A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | Aventis Pharmaceuticals Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20130005741-A1 | SUBSTITUTED PYRIMIDINE AS A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | AVENTIS PHARMACEUTICALS INC. (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2011115943-A1 | A SUBSTITUTED PYRIMIDINE AS A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | AVENTIS PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005741-A1 | SUBSTITUTED PYRIMIDINE AS A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | PTGDR2, PTGDR, PTGER2 | PTGDR 2/4885IGF1R 3457/4885ALK 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.